孟加拉国医学院前瞻性研究的同行评审结果：伊维菌素和强力霉素联合使用可有效治疗轻度至中度COVID-19
2020年9月23日
孟加拉国医学院，COVID-19，
多西环素，伊维菌素，
孟加拉国内科医生与外科学杂志
接受了Tarek Alam博士与孟加拉国医学院合作撰写的首个病例系列研究。
TrialSite在接受Alam博士采访后展示了这些结果。
标题为“用伊维菌素和强力霉素联合治疗的100例COVID-19阳性患者的病例系列”，
同行评审的结论
提示伊维菌素和强力霉素联合使用对轻度至中度患病的COVID-19患者的病毒清除非常有效。
孟加拉国这一重要医学杂志的发现，
研究结果
在该医院批准的方案中，一项前瞻性研究结合了伊维菌素和强力霉素，用于治疗感染SARS-CoV-2的轻度至中度疾病患者，
使用预定义的纳入和排除标准招募了100例感染了COVID-19的患者。
该研究包括年龄从8岁到84岁的64位男性和36位女性。
给予非标签联合治疗后，所有患者均测试阴性，其症状在72小时内显示出明显改善。
研究小组没有发现明显的副作用。
The study team
concluded in this peer-reviewed report that ivermectin and doxycycline were “found to be very effective in viral clearance in mild and moderately sick COVID-19 patients.”
Randomized Trial Moves Forward As mentioned previously, Dr. Alam informed TrialSite that the authorities in Bangladesh have approved the randomized controlled trial based on the efforts of his work to date.
TrialSite reported that Dr. Alam was first planning this study to further investigate “the People’s Medicine” back in July.
the world 8th most populated nation, are not trivial nor remote.
Rather, they reflect a growing real-world evidence that national research agencies, including the National Institutes of Health in the United States,
should undertake larger multicenter studies to validate and recommend this combination therapy to include in national COVID-19 guidelines.
Called “The People’s Medicine” in Bangladesh, the time is now for formalized study in the United States.
As COVID-19 continues to wreak havoc around the world—as of this writing, 31 million reported cases worldwide with nearly 1 million deaths (200,000 in America alone)—health, economies, and civil societies feel the growing strain.
Cost effective and widely available treatments must be found to economically and expeditiously address and contain this contagion.
A study of ivermectin isn’t a replacement for the mission-critical vaccines (Moderna, Pfizer, etc.) and powerful monoclonal antibodies under development by Regeneron, Eli Lilly and others.
Rather, they all complement another as a range of therapies at different price points are required to take on COVID-19 for the long run